Healthcare product and device company Abbott Laboratories (NYSE:ABT) fell short of the markets revenue expectations in Q4 ...

ADJUSTED EARNINGS: Stripping out certain one-time items, earnings are forecast to come in at $1.50 a share. That compares with adjusted earnings of $1.34 a share a year earlier. REVENUE: Quarterly ...

Abbott shares fell after quarterly sales and early 2026 earnings guidance missed estimates, even as the company forecast ...

Abbott Labs' nutrition business in Columbus reached a milestone in 2024, according to the company.

Healthcare product and device company Abbott Laboratories (NYSE:ABT) will be announcing earnings results tomorrow before the ...

Novo Nordisk and Eli Lilly have generated billions of dollars in revenue selling weight loss drugs. Abbott Labs is launching a complementary product for those on the weight loss path. Abbott Labs is ...

Abbott Laboratories and Decom will concentrate on competing in the huge market of potential continuous glucose monitor technology and put any patent disputes behind them for 10 years. North ...

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Abbott Laboratories has agreed to discontinue sales of its ...

Abbott Laboratories offers a compelling investment opportunity due to its resilience, consistent growth, and strong dividend record despite challenges in its COVID-19 diagnostic products and nutrition ...

A California federal judge has reportedly allowed litigation to proceed against Abbott Laboratories (NYSE:ABT) regarding its Glucerna shakes and nutritional powders. The lawsuit claims these products, ...